Zacks.com on MSN6d
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...
Zacks.com on MSN6d
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...
pharmaphorum1d
GSK asthma hope depemokimab works in second indication
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
Nasdaq6d
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...
Investing6d
GSK reports promising phase III trial results for depemokimab
GSK plc (LSE/NYSE: GSK) has announced positive outcomes from its phase III ANCHOR trials for depemokimab, a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). According to the press ...
Investing6d
GSK reports promising phase III trial results for depemokimab
GSK plc (LSE/NYSE: LON:GSK) has announced positive outcomes from its phase III ANCHOR trials for depemokimab, a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). According to the press ...
pharmaphorum3d
ERS: GSK reveals data behind new asthma hope depemokimab
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...